Drug class
Mutant isocitrate dehydrogenase-1 (IDH1) inhibitor; targeted antineoplastic
Mechanism of action
Inhibits mutant IDH1 enzymes, reducing production of the oncometabolite 2-hydroxyglutarate. This promotes differentiation of leukaemic myeloid cells and reduces the abnormal epigenetic signalling driven by mutant IDH1.
General use cases
- Treatment of adults with relapsed or refractory acute myeloid leukaemia (AML) with a susceptible IDH1 mutation detected by an FDA-approved test; specialist haematology use
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
